Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A method for detecting, screening and/or monitoring a cancer in an individual

A cancer, individual technology, applied in measurement devices, biological tests, material inspection products, etc., can solve problems such as inappropriate serum replacement measurement methods, inability to detect PSA, etc.

Inactive Publication Date: 2005-10-19
里格舒斯匹塔里特医院 +1
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

PSA is present in high concentrations in serum and plasma and to a lesser extent in urine, and in one study it was not detectable at all in saliva (Lovgren, L., Valtonen-Andre, C., Marsal, K., Lilja H. and Lundwall, A. (1999) Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids, Journal of Andrology, 20; 348-355)
[0025] Furthermore, another study has shown that determination of free and total PSA contained in saliva to improve and simplify the differentiation between prostate cancer and benign prostatic hyperplasia is not suitable as a substitute measurement for serum (Turan T, Demir S, Aybek H, Atahan O, Tuncay OL, Aybek Z, (2000) Free and total prostate-specific antigen levels in saliva and the comparison with serum levels in men. Eur Urol.; 38(5):550-4)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A method for detecting, screening and/or monitoring a cancer in an individual
  • A method for detecting, screening and/or monitoring a cancer in an individual
  • A method for detecting, screening and/or monitoring a cancer in an individual

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0082] Example 1: Determination of total concentration of TIMP-1 in saliva

[0083] An ELISA was prepared to quantify the total concentration of TIMP-1 in human plasma.

[0084] A sensitive and specific sandwich ELISA was prepared using the TIMP-1 antibody developed by the Strangeways laboratory (Hembry et al, 1985 (Hembry et al, 1985)). Sheep polyclonal anti-TIMP-1 antiserum (Hembry et al., 1985; Murphy et al., 1991 (Hembry et al., 1985; Murphy et al., 1991)) was used to capture antigen, and mouse monoclonal anti-TIMP-1 1 IgG1 (MAC-15) (Cooksley et al., 1990 (Cooksley et AL, 1990)) was used to detect the antigen.

[0085] Rabbit anti-mouse immunoglobulin / alkaline phosphatase conjugate (Lot D0314, Dako, Glostrup, Denmark) was the secondary detection reagent. The alkaline phosphatase conjugate is pre-adsorbed with human IgG prior to use, thereby excluding cross-reaction with IgG in the sample.

[0086] Since the monoclonal detection antibody MAC-15 can recognize free TIMP-1 ...

Embodiment 2

[0117] Example 2: Detection value of total TIMP-1 in patients with colorectal cancer

[0118] Total TIMP-1 levels were determined in the plasma and saliva of three colorectal cancer patients (sampling (III)) following the TIMP-1 assay described in Example 1.

[0119] Each TIMP-1 value was analyzed and compared with standard biostatistical parameters.

[0120] patient

[0121]Three patients who were undergoing elective surgery for their pathologically confirmed colorectal cancer were included in the study. Blood and saliva samples were obtained from all patients before surgery with the informed consent of all patients in accordance with the Helsinki declartion and with the approval of the local ethics committee at Hvidovre Hospital, Denmark. All patients were pathologically confirmed to have adenocarcinoma of the colon or rectum.

[0122] Determination of total concentration of TIMP-1 in sampling (III)

[0123] In sampling (III), saliva samples and plasma samples of colorec...

Embodiment 3

[0138] Example 3: Determination of the total concentration of TIMP-1:MMP-9 complex and free TIMP-1 in saliva

[0139] As shown in Example 1, the total concentration of TIMP-1 in saliva corresponds very precisely to the total concentration of TIMP-1 in plasma. Since a correlation has been found between plasma and saliva, it will be obvious to those skilled in the art to also determine the total concentration of TIMP-1:MMP-9 complex and free TIMP-1 in saliva.

[0140] Suitable methods and materials are described in the same examples of said reference WO00 / 62070. In view of the findings in Example 1, the same results were obtained for the total concentration of TIMP-1:MMP-9 complex and free TIMP-1, respectively.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Average pore sizeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to methods for screening and / or detecting and / or monitoring cancer in an individual. The method includes determining a first parameter represented by the concentration of TIMP-1 in at least one excreta from the individual, such as saliva. The present invention provides a method that can easily diagnose early-stage cancer, monitor the recurrence of cancer, and / or monitor the status of cancer or the effect of cancer treatment in an individual without using blood samples.

Description

technical field [0001] The present invention relates to a method for early detection and / or screening and / or monitoring of cancer in an individual. Background technique [0002] An important factor affecting the long-term survival of cancer patients is the stage at which the cancer is detected. Early detection, before metastases occur, facilitates the rapid and complete removal of any malignant neoplasm, as evidenced by increased cure rates and long-term survival in such patients. [0003] Furthermore, if cancer is detected, not only treatment response, but also recurrence of cancer after treatment, early detection of cancer spread, is crucial to the survival rate of cancer patients. [0004] The best method for early detection is routine screening of those considered at risk for cancer. However, existing screening methods suffer from various therapeutic limitations. They may be too expensive and / or unreliable to be widely used. In conclusion, for many cancers no practic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/543G01N33/558G01N33/574
CPCG01N2800/52G01N33/558G01N2333/8146G01N33/54366G01N33/57488
Inventor 拉塞·L·赫塞尔杰斯珀·马林尼尔斯·布吕纳马瑟·霍尔滕-安德松汉斯·约恩·尼尔森
Owner 里格舒斯匹塔里特医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com